SHANGHAI LABWAY CLINICAL LABORATORY CO., LTD

Shanghai Labway Clinical Laboratory Co., Ltd

Equities

301060

CNE100004RG8

Healthcare Facilities & Services

End-of-day quote Shenzhen S.E. Other stock markets 03:30:00 10/05/2024 am IST			5-day change	1st Jan Change
10.78 ^CNY	-5.93%		+5.69%	-18.89%

26/04	Shanghai Labway Clinical Laboratory Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
02/04	Tranche Update on Shanghai Labway Clinical Laboratory Co., Ltd's Equity Buyback Plan announced on November 16, 2023.	CI

Tranche Update on Shanghai Labway Clinical Laboratory Co., Ltd's Equity Buyback Plan announced on November 16, 2023.

April 02, 2024

From January 1, 2024 to March 31, 2024, the company has repurchased 409,700 shares, representing 0.1% for CNY 5.13 million. With this, the company has completed the repurchase of 1,161,200 shares, representing 0.29% for CNY 15.39 million under the buyback announced on November 16, 2023.

Latest news about Shanghai Labway Clinical Laboratory Co., Ltd

Shanghai Labway Clinical Laboratory Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2024	26/04	CI
Tranche Update on Shanghai Labway Clinical Laboratory Co., Ltd's Equity Buyback Plan announced on November 16, 2023.	02/04	CI
Tranche Update on Shanghai Labway Clinical Laboratory Co., Ltd's Equity Buyback Plan announced on November 16, 2023.	04/01	CI
Shanghai Labway Clinical Laboratory Co., Ltd announces an Equity Buyback for CNY 30 million worth of its shares.	16/11	CI
Shanghai Labway Clinical Laboratory Co., Ltd authorizes a Buyback Plan.	11/11	CI
Shanghai Labway Clinical Laboratory Co., Ltd Reports Earnings Results for the Nine Months Ended September 30, 2023	27/23/27	CI
Certain A Shares of Shanghai Labway Clinical Laboratory Co., Ltd. are subject to a Lock-Up Agreement Ending on 14-SEP-2023.	14/23/14	CI
Shanghai Labway Clinical Laboratory Co., Ltd Reports Earnings Results for the Half Year Ended June 30, 2023	30/23/30	CI
Labway Clinical Laboratory to Buy Enterprise Management Firm For 283 Million Yuan	10/23/10	MT
Shanghai Labway Clinical Laboratory Co., Ltd Announces Final Cash Dividend on A Shares for the Year 2022, Payable on June 20, 2023	15/23/15	CI
Shanghai Labway Clinical Laboratory Co., Ltd Approves Cash Dividend for 2022	30/23/30	CI
Shanghai Labway Clinical Laboratory Co., Ltd Proposes Final Cash Dividend for the Year 2022	28/23/28	CI
Shanghai Labway Clinical Laboratory Co., Ltd cancelled the transaction announced on September 1, 2022	27/23/27	CI
Shanghai Labway Clinical Laboratory Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2023	26/23/26	CI
Shanghai Labway Clinical Laboratory Co., Ltd Reports Earnings Results for the Full Year Ended December 31, 2022	19/23/19	CI
As China seeks to live with the virus, COVID-control industries face decline	16/22/16	RE
Chinese COVID testing firms report big profits as virus fight intensifies	03/22/03	RE
Shanghai Labway Clinical Laboratory Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022	27/22/27	CI
Shanghai Labway Clinical Laboratory Co., Ltd.(XSEC:301060) added to S&P Global BMI Index	19/22/19	CI
Certain A Shares of Shanghai Labway Clinical Laboratory Co., Ltd. are subject to a Lock-Up Agreement Ending on 14-SEP-2022.	14/22/14	CI
Shanghai Labway Plans $96 Million Share Sale to Fund New Laboratories	05/22/05	MT
Shanghai Labway Clinical Laboratory Co., Ltd. announced that it expects to receive CNY 664.4942 million in funding	01/22/01	CI
Shanghai Labway Clinical Laboratory Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022	25/22/25	CI
Jiangsu Xikang Technology Co., Ltd. announced that it expects to receive CNY 140 million in funding from Shanghai Labway Clinical Laboratory Co., Ltd	24/22/24	CI

Chart Shanghai Labway Clinical Laboratory Co., Ltd

Duration

Period

Chart Shanghai Labway Clinical Laboratory Co., Ltd

More charts

Company Profile

Shanghai Labway Clinical Laboratory Co Ltd is a company providing overall solutions for the inspection and diagnosis industry. The Company's businesses include medical testing and pathological diagnosis services and the sales of in vitro diagnosis product. The medical examination and pathological diagnosis services include pathological diagnosis, molecular examination, biochemical examination, immune examination, microbial examination, clinical basic examination and physical and chemical examination. The in vitro diagnostic products sales include in vitro diagnostic instruments, reagents and related accessories and consumables.

Sector

Healthcare Facilities & Services

Calendar

22/05/2024 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Sector Medical & Diagnostic Laboratories

	1st Jan change	Capi.
SHANGHAI LABWAY CLINICAL LABORATORY CO., LTD	-18.89%	596M
SONIC HEALTHCARE LIMITED	-16.58%	8.49B
RADNET, INC.	+58.90%	4.08B
GUANGZHOU KINGMED DIAGNOSTICS GROUP CO., LTD.	-39.78%	2.42B
SYNLAB AG	-10.33%	2.42B
DR. LAL PATHLABS LIMITED	-8.91%	2.33B
NEOGENOMICS, INC.	-2.53%	2.01B
FLEURY S.A.	-19.90%	1.53B
DIAN DIAGNOSTICS GROUP CO.,LTD.	-38.30%	1.26B
METROPOLIS HEALTHCARE LIMITED	+2.19%	1.07B

Medical & Diagnostic Laboratories